This article is for informational and educational purposes only and does not constitute medical advice. MOTS-c is supplied by Wholesale Peps as lyophilized research-grade material for in vitro laboratory use only and is not approved by the FDA for human or veterinary use.
MOTS-c is a 16-amino acid peptide encoded within the open reading frame of the mitochondrial 12S ribosomal RNA gene (MT-RNR1), making it one of the few known bioactive peptides of mitochondrial rather than nuclear genomic origin. Published cell-based and animal model research has reported associations between MOTS-c and activation of AMP-activated protein kinase (AMPK) via disruption of the intracellular folate-methionine cycle, with proposed downstream effects on glucose metabolism, insulin sensitivity, and inflammatory signaling. Observational studies have reported increases in circulating MOTS-c with exercise and declines with age, though the biological significance of these patterns in humans has not been established through controlled interventional trials. No peer-reviewed phase 1–3 clinical trials evaluating exogenous MOTS-c administration in humans have been published as of this article’s last review date; all available mechanistic evidence derives from in vitro assays and animal model experiments.
1. Background
1.1 Mitochondria-Derived Peptides — A New Class
For decades, the human mitochondrial genome was understood to encode a fixed set of products: 13 proteins (all subunits of the oxidative phosphorylation complexes), 22 transfer RNAs, and 2 ribosomal RNAs. The discovery that small open reading frames (smORFs) within mitochondrial RNA genes could encode bioactive peptides — now termed mitochondria-derived peptides (MDPs) — challenged this framework.
The first characterized MDP was humanin, identified in 2001 in a screen for neuroprotective factors encoded within the mitochondrial 16S rRNA gene. MOTS-c, discovered fourteen years later, is encoded within the 12S rRNA gene (MT-RNR1) and represents the first MDP identified with metabolic rather than primarily neuroprotective properties. Other MDPs subsequently identified include the small humanin-like peptides (SHLPs 1–6), though their functional profiles remain less extensively characterized than either humanin or MOTS-c [1].
1.2 Discovery of MOTS-c
MOTS-c was characterized by Lee et al. in a 2015 paper published in Cell Metabolism. Using bioinformatic analysis of mitochondrial open reading frames, the authors identified a conserved 16-amino acid sequence within the 12S rRNA gene and demonstrated that the corresponding synthetic peptide (MRWQEMGYIFYPRKLR) had measurable biological activity when added to cells and administered to mice.
In mouse models of diet-induced obesity and age-induced insulin resistance, systemic MOTS-c administration was reported to reduce body fat accumulation, improve glucose tolerance, and enhance insulin sensitivity. In cell-based experiments, the proposed mechanism involved disruption of the intracellular folate-methionine cycle, leading to accumulation of 5-aminoimidazole-4-carboxamide ribonucleotide (AICAR) and subsequent AMPK activation [1]. The discovery paper was produced primarily by the laboratory of Changhan David Lee at the University of Southern California, and the majority of subsequent MOTS-c research has originated from or in collaboration with the same group.
1.3 Relationship to Exercise and Aging
Subsequent research extended the initial metabolic findings. Kim et al. (2019) reported that serum MOTS-c concentrations increased following aerobic exercise in a cohort of human subjects, and that exogenous MOTS-c administration in mouse models replicated aspects of the metabolic and gene expression response to exercise — leading the authors to characterize it as a potential “exercise-mimetic” [2]. These findings prompted the World Anti-Doping Agency (WADA) to add MOTS-c to its Prohibited List in 2022 under Section S4.4 (hormone and metabolic modulators). The WADA listing reflects regulatory concern about potential performance enhancement; it does not constitute evidence of proven efficacy in competitive athletes.
Reynolds et al. (2021) demonstrated in animal studies that circulating MOTS-c levels declined with age in mice and correlated with measures of physical performance and muscle homeostasis. Exogenous MOTS-c administration in aged mice was reported to partially restore exercise capacity and alter skeletal muscle gene expression programs associated with aging [3]. These preclinical aging findings have not been replicated in controlled human trials.
2. Molecular Structure
MOTS-c is a 16-amino acid peptide with the single-letter sequence MRWQEMGYIFYPRKLR, encoded within an open reading frame of the mitochondrial 12S ribosomal RNA gene (MT-RNR1). Its expression uses the non-standard mitochondrial genetic code, in which AGA and AGG encode stop codons rather than arginine as in the nuclear genome.
| Property | Detail |
|---|---|
| Sequence (single-letter) | MRWQEMGYIFYPRKLR |
| Length | 16 amino acids |
| Molecular weight | ~2,173 Da |
| Genomic source | MT-RNR1 (mitochondrial 12S ribosomal RNA gene; open reading frame) |
| Genetic code used | Non-standard mitochondrial code (AGA/AGG = stop codons, not Arg) |
| Post-translational modifications | None identified |
| Water solubility | High (net positive charge; hydrophilic overall) |
Unlike longer peptides such as GHK-Cu or modified GLP-1 analogues, MOTS-c carries no acylation or albumin-binding modification. As a short, unmodified peptide, it would be expected to have a relatively short circulating half-life, though precise pharmacokinetic data from controlled human studies are not available.
Zempo et al. (2021) identified a naturally occurring MT-RNR1 variant (m.827A>G) that alters the MOTS-c peptide sequence, substituting glutamine for arginine at position 14 (Arg14Gln). In a Japanese cohort study, carriers of this variant showed increased type 2 diabetes risk relative to non-carriers. The authors proposed that the altered MOTS-c peptide produced by this variant had reduced metabolic activity, which the authors characterized as a “pro-diabetogenic” mitochondrial polymorphism [4]. This association, if replicated and causally established, would suggest that endogenous MOTS-c sequence variation has metabolic consequences in humans.
3. Proposed Mechanisms
The following mechanisms have been proposed in cell-based and animal model studies. None has been confirmed in controlled human interventional research.
4. Key Research Areas
| Research Area | Evidence Level | Best Available Evidence |
|---|---|---|
| Metabolic homeostasis / insulin sensitivity | Limited Animal models, cell-based |
Lee et al. 2015 (Cell Metab) |
| Exercise-induced MOTS-c changes | Limited Human observational + animal |
Kim et al. 2019 (Science Advances) |
| Physical performance / aging | Limited Animal models |
Reynolds et al. 2021 (Nat Commun) |
| Bone / musculoskeletal biology | Limited Animal models |
Ming et al. 2016 (BBRC) |
| MT-RNR1 polymorphism and diabetes risk | Limited Human cohort, observational |
Zempo et al. 2021 (Hum Mol Genet) |
4.1 Metabolic Research — The Discovery Studies
The foundational metabolic research by Lee et al. (2015) studied synthetic MOTS-c in high-fat diet (HFD)-induced and age-induced insulin-resistant mouse models. Key reported findings included: reduced body fat accumulation in HFD mice receiving MOTS-c relative to controls; improved insulin tolerance test (ITT) outcomes; and reversal of some metabolic parameters associated with age-related insulin resistance [1].
The proposed upstream mechanism — folate cycle disruption leading to AICAR accumulation and AMPK activation — was supported by metabolomics data in cell-based experiments showing altered folate-pathway intermediate concentrations following MOTS-c treatment. However, this mechanistic pathway has been proposed by and primarily studied within the same laboratory group that discovered MOTS-c, and independent replication of the proposed mechanism in human cell systems remains limited.
4.2 Exercise and Physical Performance
Kim et al. (2019) reported that serum MOTS-c concentrations were elevated in human subjects following aerobic exercise compared with resting baseline measurements, supporting the hypothesis that MOTS-c is an exercise-responsive endogenous peptide [2]. In parallel mouse experiments, exogenous MOTS-c administration was reported to produce metabolic and gene expression changes overlapping with those seen after aerobic exercise training, leading to the characterization of MOTS-c as a potential “exercise-mimetic.” This term reflects a proposed pharmacological parallel; it does not indicate that MOTS-c substitutes for or reproduces the full physiological effects of exercise in humans.
Schematic representation of relative circulating MOTS-c levels across age groups based on animal model findings (Reynolds et al., 2021 [3]). Values are approximate and not derived from published human plasma concentration studies. Do not interpret as precise human reference ranges.
Reynolds et al. (2021) used mouse models to demonstrate that MOTS-c expression and circulating levels declined with age and that this decline was associated with reduced grip strength, exercise endurance, and markers of muscle homeostasis. Exogenous systemic administration of MOTS-c in old mice was reported to partially restore physical performance measures and alter skeletal muscle gene expression toward a profile resembling younger animals [3]. These findings were reported in Nature Communications and represent the most comprehensive animal-model study of MOTS-c in the context of aging to date.
4.3 Bone and Musculoskeletal Research
Ming et al. (2016) evaluated MOTS-c in an ovariectomized (OVX) mouse model of postmenopausal bone loss. Administration of MOTS-c was reported to attenuate OVX-induced bone loss, with proposed mechanisms including AMPK-mediated inhibition of osteoclast differentiation and activity [5]. These findings have not been extended to human clinical studies and represent a single preclinical dataset.
4.4 MT-RNR1 Polymorphism and Endogenous Variation
The observational cohort study by Zempo et al. (2021) is notable because it provides indirect human evidence that endogenous MOTS-c sequence may matter metabolically. The pro-diabetogenic MT-RNR1 polymorphism (m.827A>G, resulting in Arg14Gln in MOTS-c) was associated with increased type 2 diabetes risk in a Japanese cohort of 2,622 individuals [4]. If this association reflects a causal reduction in MOTS-c metabolic activity, it would constitute indirect human evidence for the importance of endogenous MOTS-c in glucose homeostasis. However, establishing causality from a genetic association requires replication and mechanistic validation that has not yet been published.
5. Evidence Status
| Evidence Type | Current Status |
|---|---|
| Cell-based mechanistic studies | Published (Lee et al. 2015, Cell Metabolism) |
| Animal model metabolic and aging studies | Published (multiple; predominantly from the Lee laboratory) |
| Human observational data (exercise-induced changes) | Published (Kim et al. 2019, Science Advances) |
| MT-RNR1 polymorphism / human cohort association | Published (Zempo et al. 2021, Human Molecular Genetics) |
| Phase 1 human safety and pharmacokinetic trial | Not published |
| Phase 2 / Phase 3 efficacy trial | Not published |
| Regulatory submission or approval | Not applicable; no IND-stage development reported |
| Independent replication of AMPK mechanism | Limited; primarily single research group |
What We Still Don’t Know
- Human safety and tolerability: No published phase 1 trial has evaluated the safety, tolerability, or pharmacokinetics of exogenous MOTS-c administration in humans. Whether systemic MOTS-c is well-tolerated, what adverse event profile it carries, and what dose range is biologically meaningful in humans are all unanswered questions.
- Whether the proposed mechanism operates in humans: The AMPK activation pathway via folate cycle disruption was proposed in cell-based studies. Whether this mechanism is the primary driver of MOTS-c’s effects in living humans — at achievable circulating concentrations — has not been demonstrated.
- Pharmacokinetics and effective exposure: The half-life, volume of distribution, metabolic fate, and target tissue exposure of exogenous MOTS-c in humans are unknown. As a short, unmodified peptide it may face rapid proteolytic clearance, but this has not been characterized in published human studies.
- Whether the exercise-mimetic characterization translates to humans: Animal studies showed gene expression and metabolic changes resembling exercise adaptation; one human study reported elevated serum MOTS-c post-exercise. Whether exogenous administration produces meaningful performance or metabolic benefits in healthy or clinical human populations has not been tested.
- The causal significance of age-related decline: Circulating MOTS-c declines with age in animal studies. Whether this decline is a driver of age-related metabolic deterioration or an epiphenomenon of it — and whether restoring levels in humans produces benefits analogous to those seen in aged mice — remains to be established.
- How MT-RNR1 variation affects response to exogenous MOTS-c: Given that naturally occurring MT-RNR1 polymorphisms alter the MOTS-c peptide sequence and appear to affect metabolic risk, it is an open question whether individuals with different mitochondrial haplotypes would respond differently to exogenous synthetic MOTS-c.
6. Limitations of Current Research
References
- Lee C, Zeng J, Drew BG, et al. "The Mitochondrial-Derived Peptide MOTS-c Promotes Metabolic Homeostasis and Reduces Obesity and Insulin Resistance." Cell Metabolism. 2015;21(3):443–454. doi:10.1016/j.cmet.2015.02.009
- Kim SJ, Mehta HH, Wan J, et al. "Mitochondria-Derived Peptide MOTS-c Induces Physiological and Headspace Gas Changes With Implications for Doping in Sports." Science Advances. 2019;5(11):eaaw1609. doi:10.1126/sciadv.aaw1609
- Reynolds JC, Lai RW, Woodhead JST, et al. "MOTS-c is an exercise-induced mitochondrial-encoded regulator of age-dependent physical decline and muscle homeostasis." Nature Communications. 2021;12(1):470. doi:10.1038/s41467-020-20790-0
- Zempo H, Kim SJ, Fuku N, et al. "A Pro-diabetogenic mtDNA Polymorphism in the Mitochondrial-Encoded MOTS-c Peptide." Human Molecular Genetics. 2021;30(11):1048–1054. doi:10.1093/hmg/ddab075
- Ming W, Lu G, Xin S, et al. "Mitochondria related peptide MOTS-c suppresses ovariectomy-induced bone loss via AMPK activation." Biochemical and Biophysical Research Communications. 2016;476(4):412–419. doi:10.1016/j.bbrc.2016.05.135